INTRODUCTION
============

Obesity has become epidemic and is associated with increased morbidity secondary to various factors (comorbidities), including gastroesophageal reflux disease. These associated factors increase mortality[@B01] ^-^ [@B05]. Reaches 600 million people worldwide and 30 million in Brazil. Including the population with overweight, the figure rises to 1.9 billion people worldwide and 95 million Brazilians[@B03]. Obesity is defined according to body mass index (BMI) greater or equal to 30[@B01] ^-^ [@B03].

Treatment is multidisciplinary and includes dietary measures, behavioral, exercise, medications, endoscopic and surgical methods[@B01] ^,^ [@B02] ^,^ [@B06]. Surgical treatment is consistent feature in severe obesity (IMC≥40 or ≥35 associated with comorbidities) with clinical treatment failure, reducing mortality rates and improving clinical comorbidities[@B01] ^,^ [@B04]. Surgical techniques can be restrictive (adjustable gastric banding, sleeve gastrectomy), disabsortive (duodenal switch, Scopinaro operation) or mixed (Roux-en-Y gastric bypass)[@B06].

In the preoperative of patients with bariatric surgical indication, as well as history and appropriate physical examination, laboratory tests are required, including upper endoscopy (EDA). Its use in preoperatively asymptomatic patients is controversial[@B04] ^,^ [@B08] ^,^ [@B09]; however, most studies and societies recommend it in all patients[@B04] ^-^ [@B08] ^,^ [@B10] for identifying various diseases to be treated before surgery. It may also suggest modification of surgical technique to be employed and to contraindicate the operation[@B04] ^-^ [@B08]. Studies have shown endoscopic findings in 80% of asymptomatic patients[@B07] ^,^ [@B08].

The most frequent endoscopic findings are hiatal hernia, gastritis, esophagitis, gastroduodenal ulcers and Barrett\'s esophagus[@B04] ^,^ [@B07] ^,^ [@B08]. The stomach is the most affected segment up about 80% of the cases[@B05].

The prevalence of *Helicobacter pylori* infection in individuals with bariatric surgery indication in the literature ranges from 8,7%[@B05] to 30-40%[@B04] ^,^ [@B11] of cases. It is recommended its search and pre-operative treatment[@B04], since it is associated with higher incidence of gastric cancer[@B12] and anastomotic mouth ulcers[@B04].

The aim of this study was to analyze the EDA results in patients who were in pre-bariatric surgery, and underwent the procedure at the Endoscopy Unit of the Santa Casa de São Paulo, São Paulo, SP, Brazil, and compare them to findings in control group.

METHOD
======

This study was approved by the Ethics Committee of the Santa Casa de São Paulo. The subjects involved were in agreement and consented to participate in the research and dissemination of its results in accordance with Resolution 196/96 of the National Health Council.

Patients
========

The sample consisted of two groups, one being the control group. Were analyzed 35 patients in the group of obese in the preoperative period for bariatric surgery and 30 non-obese in the control group. The number of cases was calculated to obtain sample force power to 80% and significance level of 5% (p=0.05). All patients underwent endoscopy during the period from February to July 2014.

Were included in the study group those patients appointment to preoperative bariatric surgery survey. Were excluded those who refused to participate.

The control group was formed by a pairing of patients according to gender, age and use of proton pump inhibitors (PPIs). The age of the control group was established by calculating the average age range of bariatric patients, using 95% confidence interval.

Were included patients in the control group that had indication for EDA and with lower BMI than or equal to 29.9, being normal (BMI: 18.5 to 24.9) or overweight (BMI 25 to 29.9). Were excluded obese patients (BMI≥30) and the ones with gastrointestinal tract malignancy, stenosis, having prior gastrointestinal surgery or refused to participate.

The variables analyzed were age, BMI, use of PPIs, symptoms, endoscopic findings, complications of the procedure, prevalence of infection of *Helicobacter pylori.*

Endoscopy
=========

Patients underwent to a questionnaire (protocol), followed by the completion of the endoscopic examination with standard 9.8 mm videoendoscope under sedation and topical anesthesia. The research for *Helicobacter pylori* was done by two methods: pathology and urease test, given as positive if any one of them was positive. Endoscopic findings were divided into ulceropeptic disease - gastritis, bulboduodenitis and peptic ulcers -; associated with gastroesophageal reflux disease - esophagitis, hiatal hernia, Barrett\'s esophagus -; polyps; others (diverticula, gastric intestinal metaplasia, etc.)

Statistical analysis
====================

For the organization of the data was used the spreadsheet MS-Excel version of MS-Office 2010, and to achieve the results was used IBM SPSS (Statistical Package for Social Sciences), version 22.0. The qualitative variables were represented by absolute frequency (n) and relative (%) and quantitative by average, standard deviation and median (md). Applying the Spearman, correlation analysis was performed in order to verify the degree of relationship between some of the variables. The application of Fisher\'s exact test was performed to verify possible differences between both groups for the variables of interest. The correlation coefficient (r) between the variables was determined as positive or negative. The significance level (p) was considered as less than 5% (p\<0.05).

RESULTS
=======

The average age of the group of patients was 43.54 years (25-64) and the control group of 40.53 years (38-44) ([Table 1](#t1){ref-type="table"}).

TABLE 1- Distribution of patients and the control group according to age and BMI**VariableGroupnMeanStandarddeviationMinimumMaximumPercentile 25Percentile 50 (median)Percentile 75**AgePatient3543,5410,9425,0064,0036,0042,0054,00Control3040,531,7038,0044,0039,0040,5042,00IMCPatient3547,266,2138,0068,0043,1045,9049,50Control3024,211,9821,0028,0022,6823,8025,90

Most individuals of both groups, patients and control, were women in 91.4% and 83.3%, respectively ([Table 2](#t2){ref-type="table"}).

TABLE 2- Distribution of patient and the control groups by categorical variables**VariableCategoryGroupPatientControlFreq.Perc.Freq.Perc.**GenderF3291,40%2583,30%M38,60%516,70%BMINormal00,00%2170,00%Overweight00,00%930,00%PPI userYes514,30%1653,30%No3085,70%1446,70%SymptomaticYes38,60%2480,00%No3291,40%620,00%PyrosisYes25,70%826,70%No3394,30%2273,30%RegurgitationYes12,90%723,30%No3497,10%2376,70%EpigastralgiaYes12,90%1860,00%No3497,10%1240,00%Other symptomYes12,90%13,30%No3497,10%2996,70%NormalYes720,00%1033,30%No2880,00%2066,70%Endoscopic finding - DUPYes2057,10%1550,00%No1542,90%1550,00%Endoscopic finding - DRGEYes1234,30%723,30%No2365,70%2376,70%Endoscopic finding - polypYes411,40%26,70%No3188,60%2893,30%Endoscopic finding - othersYes38,60%26,70%No3291,40%2893,30%Helicobacter pyloriPositive2160,00%1240,00%Negative1440,00%1860,00%[^2]

The average value of BMI in the group of patients was 47.26 kg/m^2^ (38-68) and in the control group of 24.21 kg/m^2^ (21-28) ([Table 1](#t1){ref-type="table"}). Only one individual of patient group had BMI below 40 kg/m^2^. Most of the control group was of normal individuals (70%).

The ones analyzed in the group of patients, 30 (85.7%) did not use PPIs and five (14.3%) yes. Sixteen of control group (53.3%) used PPIs and 14 did not ([Table 2](#t2){ref-type="table"}).

Most patients were asymptomatic (91.4%); in the three symptomatic the most prevalent symptom was heartburn. Most control subjects were symptomatic (80%). The most prevalent symptom was epigastric pain.

Twenty-eight (80%) patients had endoscopy with alterations and seven (20%), normal. In the control group ten (33.3%) had normal results and 20 (66.7%) amended ([Table 2](#t2){ref-type="table"}). Twenty-six (81.25%) of the 32 asymptomatic patients had endoscopy with alterations.

The endoscopic changes in the patient group were 57.1% (n=20) resulting from ulceropeptic disease, 34.3% (n=12) associated with reflux disease, 11.4% (n=4) showed benign polyps and 8.6% (n=3) other findings - Zenker\'s diverticulum, esophageal and gastric intestinal metaplasia, subepithelial lesions ([Figure 1](#f1){ref-type="fig"}, [Table 2](#t2){ref-type="table"})

FIGURE 1- Endoscopic findings in patients groupDUP= ulceropeptic disease; DRGE=reflux disease

In the group of patients, the analysis of correlation between the increase in the value of BMI and the incidence of endoscopic findings was not statistically significant ([Table 3](#t3){ref-type="table"}). In the control group, the endoscopic findings were 50% (n=15) resulting from ulceropeptic disease, 23.3% (n=7) associated with reflux disease, two had benign polyps and two other findings, which were ectopic pancreas and ectopic gastric mucosa in proximal esophagus ([Figure 2](#f2){ref-type="fig"}; [Table 2](#t2){ref-type="table"}).

TABLE 3- Correlation analysis between the increase in the value of BMI and the incidence of endoscopic findings**VariableStatisticIMC**DUPCorrelation coefficient (r)+0,031Calculated significance (p)0,858n35DRGECorrelation coefficient (r)-0,271Calculated significance (p)0,115n35PolypCorrelation coefficient (r)+0,013Calculated significance (p)0,939n35OthersCorrelation coefficient (r)+0,207Calculated significance (p)0,232n35[^3]

The analysis of the number of endoscopic findings in patients and in the control group did not show statistically significant differences ([Table 4](#t4){ref-type="table"}).

FIGURE 2- Endoscopic findings in control groupDUP= ulceropeptic disease; DRGE=reflux disease

TABLE 4- Analysis of endoscopic findings of the patients group compared to the control group**VariableCategoryGrouppPatientControlFreq.Perc.Freq.Perc.**DUPYes2057,10%1550,00%0,565No1542,90%1550,00%DRGEYes1234,30%723,30%0,333No2365,70%2376,70%PolypYes411,40%26,70%0,508No3188,60%2893,30%OthersYes38,60%26,70%0,774No3291,40%2893,30%[^4]

The prevalence of *Helicobacter pylori* infection was 60% (n=21) individuals in the group of patients and in 40% (n=12) in the control group ([Table 2](#t2){ref-type="table"}).

DISCUSSION
==========

In this study, 97.1% (n=34) of patients preoperatively showed IMC≥40, being included, therefore, in a group of severely obese, whose surgical treatment may bring good results.

There are studies showing that most individuals in the preoperative bariatric surgery does not have symptoms of reflux[@B05]. In this study, the majority of individuals in the group of patients were asymptomatic (91.4%) and 30 (85.7%) did not use PPIs. The most common symptoms were heartburn and epigastric pain between symptomatic individuals from groups of patients and control.

There is published data that showed endoscopic findings in patients in the preoperative bariatric surgery ranging between 9.5% and 90%, most of them between 18% and 54%[@B09].

In this study, 81.25% (n=26) of asymptomatic individuals in the group of patients had alterations in endoscopic examination, confirming some studies showing endoscopic findings in 80% of asymptomatic patients[@B07] ^,^ [@B08].

Endoscopic changes in the patient group were 57.1% (n=20) resulting from ulceropeptic disease and 34.3% (n=12) associated with reflux disease, corroborating data in the literature which show that the most frequent endoscopic findings are gastritis, hiatal hernia, esophagitis and gastroduodenal ulcers[@B04] ^,^ [@B07] ^,^ [@B08]. Individuals analyzed in this study had no endoscopic finding that could contraindicate bariatric surgery.

In the group of patients, the analysis of correlation between the increase in the value of BMI and the incidence of endoscopic findings was not statistically significant, suggesting that there is no relationship between the degree of obesity and the occurrence of endoscopic changes.

The analysis of the number of endoscopic findings in patients in the control group did not show statistically significant differences, which may suggest that obese individuals have no higher probability of having endoscopic changes.

The prevalence of *Helicobacter pylori* in this study was 60% (n=21) in the group of patients. In the literature, its prevalence in individuals with bariatric surgery indication varies from 8,7%[@B05] a 30-40%[@B04] ^,^ [@B11]. The finding of this study may have been due to the use of two methods for the bacteria search (urease test and histology), which increased the accuracy. One should also take into account that there are papers that used only one diagnostic method and others investigated*Helicobacter pylori* only in part of their series. However, it is recommended to look for and treat it in the pre-operative period, since it is associated with higher incidence of gastric cancer[@B12] and mouth ulcers in the anastomoses[@B04].

CONCLUSION
==========

It is recommended that endoscopy should be performed in all patients in the preoperative of bariatric surgery, although the degree of obesity is unrelated to larger endoscopic changes. The obese do not have more endoscopic changes than the non-obese.
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